Skip to Content

Ralph S. Freedman, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Clinical Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

 I retired in 2007 from a full-time facultyappointment as Professor in the Department of Gynecologic Oncology after 31years of a productive career in clinical, educational and well-funded researchactivities. Since 2007 I have a part-time clinical appointment as ClinicalProfessor of Gynecologic Oncology with my clinical service appointment atthe Lyndon Baines Johnson County Hospital where I also teach residents andmedical students. During my tenure, my main research activities werefocused on the immune-biology and immunotherapy of gynecologic cancersespecially ovarian cancer. I have over 200 peer-reviewed publications andwas Co-series editor of the popular MD Anderson Cancer Care series.  Myresearch was funded by NIH, ACS and the Texas State in addition to a number ofpharma sponsored trials. My main academic achievements included the primarymentorship of 2 basic science PhD students, 1 student from the MD. PhD programand the PhD thesis of an overseas MD . I also served on multiple committees forthe graduate student program.  During my tenured career I also served onmultiple NIH study sections and in 2000-2006 was appointed by President Clintonto the National Cancer Advisory Board where I also served as chair of theSpecial Committee that conducts final review of NCI grantsUntil 2013 I servedas Chair of the executive IRB at MD Anderson Cancer Centre and currentlyparticipate in the annual Human Subjects training of graduate students. Icurrently serve as sub investigator on GOG and other trials and am mentor tofaculty in the development of immunotherapy studies. I I am an adhoc reviewerof drugs and device studies presented at FDA advisory committees and completeda 3 year appointment on ODAC in 2013.   I continue to serve on theeditorial review board for Clinical Cancer Research and otherinternational journals.

 

 

 

Education & Training

Degree-Granting Education

1975 Witwatersrand University, Johannesburg, South Africa, PHD, Medicine
1965 Witwatersrand University, Johannesburg, South Africa, MBBCh, Medicine

Postgraduate Training

1977 External Beam, Interstitial and Intracavitary Dosimetry: Manual and Computer Methods Calculation, The University of Texas MD Anderson Cancer Center, Houston, TX
1976 Fellowship, Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
1968-1971 Residency, Obstetrics and Gynecology, Johannesburg Group of Teaching Hospitals (Rotation through Queen Victoria, Johannesburg and Baragwanath Hospitals), Johannesburg, South Africa
1/1968-6/1968 Senior Internship, General Surgery and Urology, Baragwanath Hospital, Johannesburg, South Africa
1967 Gynecology, Johannesburg General Hospital, Johannesburg, South Africa
1967 Obstetrics, Queen Victoria Maternity Hospital, Johannesburg, South Africa
1966 Internship, General Surgery and Medicine, Johannesburg General Hospital, Johannesburg, South Africa

Board Certifications

1/1980 American College of Obstetrics and Gynecology, Inc
1/1971 Royal College of Obstetricians and Gynecologists (M.R.C.O.G., London)
1/1970 South Africa College of Physicians/Surgeons/Gynecology

Honors and Awards

2013 Texas Medical Association Honor Member for Notable Contributions and Outstanding Service to the Profession of Medicine and to the People of Texas, Texas Medical Association House of Delegates

Selected Publications

Peer-Reviewed Original Research Articles

1. Freedman RS, Cantor SB, Merriman KW, Edgerton ME. 2013 HIPAA Changes Provide Opportunities and Challenges for Researchers: Perspectives from a Cancer Center. Clinical Cancer Research. In Press.
2. Freedman RS, McKinney R. Is conflict of interest becoming a challenge for institution-based institutional review boards? Clin Cancer Res 19(15):4034-9, 8/2013. e-Pub 6/2013. PMID: 23741065.
3. Conrad C, Gregorio J, Wang YH, Ito T, Meller S, Hanabuchi S, Anderson S, Atkinson N, Ramirez PT, Liu YJ, Freedman R, Gilliet M. Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells. Cancer Res 72(20):5240-9, 10/2012. e-Pub 7/2012. PMCID: PMC3652570.
4. Telesca D, Muller P, Parmigiani G, Freedman RS. Modeling dependent gene expression. The Annals of Applied Statistics 20:1-19, 2012.
5. Teoh D, Freedman R, Soliman PT. Nearly 30 Years of Treatment for Recurrent Granulosa Cell Tumor of the Ovary: A Case Report and Review of the Literature. Case Rep Oncol 3(1):14-18, 2010. e-Pub 1/2010. PMCID: PMC2918836.
6. Pappas J, Wolfson AD, Jung WJ, Oleszak EL, Helm CW, Freedman RS, Tsygankov AY, Platsoucas CD. Differential expression of CD3zeta message and protein in tumor infiltrating lymphocytes from solid tumor specimens and malignant ascites from patients with ovarian carcinoma. Anticancer Res 29(11):4673-82, 11/2009. PMID: 20032419.
7. Schmeler KM, Vadhan-Raj S, Ramirez PT, Apte SM, Cohen L, Bassett RL, Iyer RB, Wolf JK, Levenback CL, Gershenson DM, Freedman RS. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol 113(2):210-5, 5/2009. e-Pub 3/2009. PMID: 19264351.
8. Kobayashi R, Deavers M, Patenia R, Rice-Stitt T, Halbe J, Gallardo S, Freedman RS. 14-3-3 zeta protein secreted by tumor associated monocytes/macrophages from ascites of epithelial ovarian cancer patients. Cancer Immunol Immunother 58(2):247-258, 2/2009. e-Pub 7/2008. PMID: 18618111.
9. Freedman RS, Ma Q, Wang E, Gallardo ST, Gordon IO, Shin JW, Jin P, Stroncek D, Marincola FM. Migration deficit in monocyte-macrophages in human ovarian cancer. Cancer Immunol, Immunother 57:635-645, 2008.
10. Cole ME. Freedman RS, Thaker P, Landen C, Broaddus R. Placental site trophoblastic tumors: a case of resistant pulmonary metastasis. Nature Clinical Practice Oncology 5/3:171-175, 2008.
11. Lenzi R, Edwards R, June CH, Seiden M, Garcia ME, Rosenblum M, Freedman RS. Phase II study of intaperitoneal recomibinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease <1 cm) associated with ovarian cancer or primary peritoneal carcinoma. J Trans Med 5:66, 12/2007.
12. Auzenne E, Ghosh SC, Khodadadian M, Rivera B, Farquhar D, Price RE, Ravoori M, Kundra V, Freedman RS, Klostergaard J. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44 (+) human ovarian carcinoma xenografts. Neoplasia 9:479-486, 7/2007.
13. Melichar B, Patenia R, Gallardo S, Melicharova K, Hu W, Freedman RS. Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines. Gynecol Oncol 104:707-13, 3/2007. PMID: 17166566.
14. Bast RC, Thigpen J, Arbuck SG, Basen-Engquist K, Burke LB, Freedman RS, Horning SJ, Ozols R, Rustin GJ, Spriggs D, Wenzel LR, Pazdur R. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR public workshop. Gynecologic Oncology 107:173-176, 2007.
15. Freedman RS, Wang E, Voiculescu S, Patenia R, Bassett RL. Deavers M, Marincola FM, Yang P, Newman RA. Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer. Clin Cancer Res 13(19):5736-5744, 2007.
16. Wang X, Fu S, Freedman RS, Liu J, Kavanagh JJ. Immunobiology of gestational trophoblastic diseases. Int J Gynecol Cancer 16:1500-15, 7/2006. PMID: 16884358.
17. Basil CF, Zhao Y, Zavaglia K, Jin P, Panelli MC, Voiculescu S, Mandruzzato S, Lee HM, Seliger B, Freedman RS, Taylor PR, Hu N, Zanovello P, Marincola FM, Wang E. Common cancer biomarkers. Cancer Res 66:2953-61, 3/2006. PMID: 16540643.
18. Gordon IO, Freedman RS. Defective antitumor function of monocyte-derived macrophages from epithelial ovarian cancer patients. Clin Cancer Res 12:1515-24, 3/2006. PMID: 16533776.
19. Apte SM, Vadhan-Raj S, Cohen L, Bassett RL, Gordon IO, Levenback CF, Ramirez PT, Gallardo ST, Patenia RS, Garcia ME, Iyer RB, Freedman RS. Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin. J Transl Med 4:16, 2006. PMID: 16603073.
20. Wang X, Deavers M, Patenia R, Bassett RL, Jr, Mueller P, Ma Q, Wang E, Freedman RS. Monocyte/macrophage and T-cell infiltrates in peritoneum of patients with ovarian cancer or benign pelvic disease. J Transl Med 4:30, 2006. PMID: 16824216.
21. Melichar B, Solichova D, Freedman RS. Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int J Gynecol Cancer 16:240-52, 2006. PMID: 16445639.
22. Wang X, Fu S, Freedman RS, Kavanagh JJ. Venous thromboembolism syndrome in gynecological cancer. Int J Gynecol Cancer 16 Suppl 1:458-71, 2006. PMID: 16515646.
23. Wang X, Wang E, Kavanagh JJ, Freedman RS. Ovarian cancer, the coagulation pathway, and inflammation. J Transl Med 3:25, 6/2005. PMID: 15969748.
24. Pappas J, Jung WJ, Barda AK, Lin WL, Fincke JE, Purev E, Radu M, Gaughan J, Helm CW, Hernandez E, Freedman RS, Platsoucas CD. Substantial proportions of identical beta-chain T-cell receptor transcripts are present in epithelial ovarian carcinoma tumors. Cell Immunol 234:81-101, 4/2005. PMID: 16038891.
25. See HT, Freedman RS, Kudelka AP, Burke TW, Gershenson DM, Tangjitgamol S, Kavanagh JJ. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int J Gynecol Cancer 15:209-16, 3/2005. PMID: 15823101.
26. Hu W, Kavanagh JJ, Deaver M, Johnston DA, Freedman RS, Verschraegen CF, Sen S. Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. Oncol Res 15:49-57, 2005. PMID: 15839305.
27. Monos D, Pappas J, Magira EE, Gaughan J, Aplenc R, Sakkas L, Freedman, RS, Reveille JC, Platsoucas CD. Identification of HLA-DQa1 residues associated with susceptibility and protection to epithelial ovarian cancer. Human Immunology 65:554-562, 2005.
28. Wang E, Ngalame Y, Panelli MC, Nguyen-Jackson H, Deavers M, Mueller P, Hu W, Savary CA, Kobayashi R, Freedman RS, Marincola FM. Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res 11:113-22, 2005. PMID: 15671535.
29. Wang E, Panelli MC, Zavaglia K, Mandruzzato S, Hu N, Taylor PR, Seliger B, Zanovello P, Freedman RS, Marincola FM. Melanoma-restricted genes. J Transl Med 2:34, 10/2004. PMID: 15488140.
30. Donato ML, Aleman A, Champlin RE, Saliba RM, Wharton JT, Burke TW, Bodurka DC, Bevers MW, Levenback CF, Wolf JK, Bast RC, Freedman RS, Ippoliti C, Brewer M, Gajewski JL, Gershenson DM. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 33:1219-24, 6/2004. PMID: 15122311.
31. Melichar B, Konopleva M, Hu W, Melicharova K, Andreeff M, Freedman RS. Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-gamma expression. Gynecol Oncol 93:149-54, 4/2004. PMID: 15047229.
32. Borchardt PE, Vriesendorp HM, Freedman RS, Quadri SM. Intralesional radioimmunotherapy with Yttrium-90-labeled human monoclonal IgM in nude mice bearing human tumor xenografts. Cancer Biother Radiopharm 19(1):43-51, 2/2004. PMID: 15068610.
33. Freedman RS, Vadhan-Raj S, Butts C, Savary C, Melichar B, Verschraegen C, Kavanagh JJ, Hicks ME, Levy LB, Folloder JK, Garcia ME. Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas. Clin Cancer Res 9(14):5228-37, 11/2003. PMID: 14614003.
34. Hu W, Wu W, Verschraegen CF, Chen L, Mao L, Yeung SC, Kudelka AP, Freedman RS, Kavanagh JJ. Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor. Proteomics 3:1904-11, 10/2003. PMID: 14625852.
35. Melichar B, Savary CA, Patenia R, Templin S, Melicharova K, Freedman RS. Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma. Int J Gynecol Cancer 13:435-43, 7/2003. PMID: 12911719.
36. Platsoucas CD, Fincke JE, Pappas J, Jung WJ, Heckel M, Schwarting R, Magira E, Monos D, Freedman RS. Immune responses to human tumors: development of tumor vaccines. Anticancer Res 23:1969-96, 5/2003. PMID: 12894571.
37. Melichar B, Lenzi R, Rosenblum M, Kudelka AP, Kavanagh JJ, Melicharova K, Templin S, Garcia ME, Abbruzzese JL, Freedman RS. Intraperitoneal fluid neopterin, nitrate, and tryptophan after regional administration of interleukin-12. J Immunother 26:270-6, 5/2003. PMID: 12806280.
38. Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M, Freedman RS, Bast RC, Jr, Kudelka AP, Kavanagh JJ, Giovanella BC. Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. Clin Cancer Res 9:845-52, 2/2003. PMID: 12576458.
39. Melichar B, Hu W, Patenia R, Melicharova K, Gallardo ST, Freedman R. rIFN-mediated growth suppression of platinum-sensitive and –resistant ovarian tumor cell lines not dependent upon arginase inhibition. J Translational Med 1:5, 2003.
40. Lenzi R, Rosenblum M, Verschraegen C, Kudelka AP, Kavanagh JJ, Hicks ME, Lang EA, Nash MA, Levy LB, Garcia ME, Platsoucas CD, Abbruzzese JL, Freedman RS. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res 8:3686-95, 12/2002. PMID: 12473577.
41. Gordinier ME, Kudelka AP, Kavanagh JJ, Wharton JT, Freedman RS. Thiotepa in combination with cisplatin for primary epithelial ovarian cancer: a phase II study. Int J Gynecol Cancer 12:710-4, 11/2002. PMID: 12445247.
42. Vadhan-Raj S, Kavanagh JJ, Freedman RS, Folloder J, Currie LM, Bueso-Ramos C, Verschraegen CF, Narvios AB, Connor J, Hoots WK, Broemeling LD, Lichtiger B. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomized cross-over study. Lancet 359:2145-52, 6/2002. PMID: 12090979.
43. Nash MA, Deavers MT, Freedman RS. The expression of decorin in human ovarian tumors. Clin Cancer Res 8:1754-60, 6/2002. PMID: 12060613.
44. Hu W, Verschraegen CF, Wu WG, Nash M, Freedman RS, Kudelka A, Kavanagh JJ. Activity of ALRT 1550, a new retinoid, with interferon-gamma on ovarian cancer cell lines. Int J Gynecol Cancer 12:202-7, 3/2002. PMID: 11975681.
45. Hu W, Wu W, Yeung SC, Freedman RS, Kavanagh JJ, Verschraegen CF. Increased expression of heat shock protein 70 in adherent ovarian cancer and mesothelioma following treatment with manumycin, a farnesyl transferase inhibitor. Anticancer Res 22:665-72, 3/2002. PMID: 12014635.
46. Zavadova E, Savary CA, Templin S, Verschraegen CF, Freedman RS. Maturation of dendritic cells from ovarian cancer patients. Cancer Chemother Pharmacol 48:289-96, 10/2001. PMID: 11710629.
47. Donato ML, Gershenson DM, Wharton JT, Ippoliti CM, Aleman AS, Bodurka-Bevers D, Bevers MW, Burke TW, Levenback CF, Wolf JK, Freedman RS, Bast RC, Jr, Gajewski JL, Champlin RE. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Gynecol Oncol 82(3):420-6, 9/2001. PMID: 11520135.
48. Hosing C, Freedman RS, McLaughlin P, Malpica A, Fornage BD, Kudelka AP. Diffuse large B-cell non-Hodgkin's lymphoma presenting as a vaginal mass in a patient with a history of intestinal mucosa-associated lymphoid tissue (MALT) lymphoma. Am J Clin Oncol 24(2):204-8, 4/2001. PMID: 11319299.
49. Manzullo E, Escalante C, Weiser MA, Freedman RS, Forman A. Case report : An elderly woman with an ovarian mass and myasthenia gravis. Resident & Staff Physician 47:55-61, 2001.
50. Azevedo P, Verschraegen CF, Kavanagh JJ, Kudelka AP, Freedman RS, Lu K, Deavers MT. Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report. Eur J Gynaecol Oncol 22:319-21, 2001. PMID: 11766729.
51. Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin Cancer Res 6:2268-78, 6/2000. PMID: 10873077.
52. Hu W, Wu W, Nash MA, Freedman RS, Kavanagh JJ, Verschraegen CF. Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancer cell lines. Anticancer Res 20:729-33, 3/2000. PMID: 10810347.
53. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, Broxmeyer HE, Kudelka AP, Freedman RS, Edwards CL, Gershenson D, Jones D, Ashby M, Kavanagh JJ. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 132(5):364-8, 3/2000. PMID: 10691586.
54. Borchardt PE, Quadri SM, Freedman RS, Vriesendorp HM. Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis. Cancer Biother Radiopharm 15:53-64, 2/2000. PMID: 10740653.
55. Melichar B, Nash MA, Lenzi R, Platsoucas CD, Freedman RS. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis. Clin Exp Immunol 119:19-27, 2000. PMID: 10606960.
56. Ferrandina G, Filippini P, Ferlini C, Maggiano N, Stoler AB, Fruscella E, Mozzetti S, Mancuso S, Freedman RS, Scambia G, Ranelletti FO. Growth inhibitory effects and radiosensitization induced by fatty aromatic acids on human cervical cancer cells. Oncol Res 12(9-10):429-40, 2000. PMID: 11697821.
57. Donato ML, Gershenson D, Ippoliti C, Wharton JT, Bast RC, Jr, Aleman A, Anderlini P, Gajewski JG, Giralt S, Molldrem J, Ueno N, Lauppe J, Korbling M, Boyer J, Bodurka-Bevers, D, Bevers M, Burke T, Freedman R, Wolf J, Champlin RE. Intensive-dose ifosfamide and etopsoide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplant 25:1137-1140, 2000.
58. Loercher AE, Nash MA, Kavanagh JJ, Platsoucas CD, Freedman RS. Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol 163:6251-60, 12/1999. PMID: 10570318.
59. Nash MA, Loercher AE, Freedman RS. In vitro growth inhibition of ovarian cancer cells by decorin: synergism of action between decorin and carboplatin. Cancer Res 59:6192-6, 12/1999. PMID: 10626812.
60. Gordinier ME, Zhang HZ, Patenia R, Levy LB, Atkinson EN, Nash MA, Katz RL, Platsoucas CD, Freedman RS. Quantitative analysis of transforming growth factor beta 1 and 2 in ovarian carcinoma. Clin Cancer Res 5:2498-505, 9/1999. PMID: 10499625.
61. Verschraegen CF, Gupta E, Loyer E, Kavanagh JJ, Kudelka AP, Freedman RS, Edwards CL, Harris N, Steger M, Steltz V, Giovanella BC, Stehlin JS. A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anticancer Drugs 10(4):375-83, 4/1999. PMID: 10378672.
62. Nash MA, Ferrandina G, Gordinier M, Loercher A, Freedman RS. The role of cytokines in both the normal and malignant ovary. Endocr Relat Cancer 6(1):93-107, 3/1999. PMID: 10732792.
63. Zavadova E, Loercher A, Verstovsek S, Verschraegen CF, Micksche M, Freedman RS. The role of macrophages in antitumor defense of patients with ovarian cancer. Current Therapeutic Issues in Gynecologic Cancer 13:135-44, 2/1999. PMID: 10080073.
64. Kudelka AP, Verschraegen CF, Shen Y, Gonzalez De Leon C, Edwards CL, Freedman RS, Forman A, Gibbs HR, Mante R, Hord M, Canetta R, Krakoff I, Kavanagh JJ. Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma. Int J Gynecol Cancer 9:44-53, 1999. PMID: 11240742.
65. Melichar B, Ferrandina G, Verschraegen CF, Loercher A, Abbruzzese JL, Freedman RS. Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines. Clin Cancer Res 4(12):3069-76, 12/1998. PMID: 9865922.
66. Nash MA, Lenzi R, Platsoucas CD, Freedman RS. RT-PCR quantitation of cytokine responses in vivo from specimens containing small numbers of cells during bioimmunotherapy. J Immunol Methods 219(1-2):169-79, 10/1998. PMID: 9831398.
67. Kudelka AP, Hasenburg A, Verschraegen CF, Edwards CL, Meyers CA, Varma D, Freedman RS, Forman A, Conrad CA, Grove W, Grothey A, Kavanagh JJ. Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. Anticancer Drugs 9(5):405-9, 6/1998. PMID: 9660537.
68. Nash MA, Lenzi R, Edwards CL, Kavanagh JJ, Kudelka AP, Verschraegen CF, Platsoucas CD, Freedman RS. Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines. Clin Exp Immunol 112(2):172-80, 5/1998. PMID: 9649178.
69. Borchardt PE, Quadri SM, Freedman RS, Vriesendorp HM. Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice. J Nucl Med 39(3):476-84, 3/1998. PMID: 9529295.
70. Melichar B, Savary C, Kudelka AP, Verschraegen C, Kavanagh JJ, Edwards CL, Platsoucas CD, Freedman RS. Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. Clin Cancer Res 4(3):799-809, 3/1998. PMID: 9533550.
71. Verschraegen CF, Natelson EA, Giovanella BC, Kavanagh JJ, Kudelka AP, Freedman RS, Edwards CL, Ende K, Stehlin JS. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs 9(1):36-44, 1998. PMID: 9491790.
72. Verschraegen CF, Kudelka AP Loyer E, Edwards CL, Freedman RS, Kavanagh JJ. A phase II trial of high-dose hydroxyurea administered parenterally in patients with epithelial ovarian carcinoma refractory to platinum. Int J Gynecol Cancer 8:494-498, 1998.
73. Freedman RS, Lenzi R, Kukelka, AP, Lawrence, DD, Rosenblum, M, Platsoucas, CD. Intraperitoneal immunotherapy of peritoneal carcinomatosis. Cytokines, Cellular & Molecular Therapy 4:121-140, 1998.
74. Savary CA, Grazziutti ML, Melichar B, Przepiorka D, Freedman RS, Cowart RE, Cohen DM, Anaissie EJ, Woodside DG, McIntyre BW, Pierson DL, Pellis NR, Rex JH. Multidimensional flow-cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients. Cancer Immunol Immunother 45(5):234-40, 1998. PMID: 9439646.
75. Ferrandina G, Melichar B, Loercher A, Verschraegen CF, Kudelka AP, Edwards CL, Scambia G, Kavanagh JJ, Abbruzzese JL, Freedman RS. Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro. Cancer Res 57(19):4309-15, 10/1997. PMID: 9331092.
76. Kudelka AP, Levy T, Verschraegen CF, Edwards CL, Piamsomboon S, Termrungruanglert W, Freedman RS, Kaplan AL, Kieback DG, Meyers CA, Jaeckle KA, Loyer E, Steger M, Mante R, Mavligit G, Killian A, Tang RA, Gutterman JU, Kavanagh JJ. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res 3(9):1501-5, 9/1997. PMID: 9815836.
77. Borchardt PE, Quadri SM, Freedman RS, Vriesendorp HM. Intralesional radiolabeled human monoclonal IgM in human tumor xenografts. Radiother Oncol 44(3):283-93, 9/1997. PMID: 9380829.
78. Kudelka AP, Siddik ZH, Tresukosol D, Edwards CL, Freedman RS, Madden TL, Rastogi R, Hord M, Kim EE, Tornos C, Mante R, Kavanagh JJ. A phase II and pharmacokinetic study of enloplatin in patients with platinum refractory advanced ovarian carcinoma. Anticancer Drugs 8(7):649-56, 8/1997. PMID: 9311439.
79. Kudelka AP, Winn R, Edwards CL, Downey G, Greenberg H, Dakhil SR, Freedman RS, LoCoco S, Umbreit J, Delmore JE, Arbuck S, Loyer E, Gacrama P, Fueger R, Kavanagh JJ. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs 8(7):657-61, 8/1997. PMID: 9311440.
80. Verschraegen CF, Levy T, Kudelka AP, Llerena E, Ende K, Freedman RS, Edwards CL, Hord M, Steger M, Kaplan AL, Kieback D, Fishman A, Kavanagh JJ. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 15(2):625-31, 2/1997. PMID: 9053486.
81. Kooi S, Zhang HZ, Patenia R, Edwards CL, Platsoucas CD, Freedman RS. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2. Cell Immunol 174(2):116-28, 12/1996. PMID: 8954611.
82. Freedman RS, Gibbons JA, Giedlin M, Kudelka AP, Kavanagh JJ, Edwards CL, Carrasco CH, Nash MA, Platsoucas CD. Immunopharmacology and cytokine production of a low-dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma. J Immunother 19:443-51, 11/1996. PMID: 9041464.
83. Vriesendorp HM, Quadri SM, Jaeckle KA, Freedman RS, Cromeens DM. Proposal for translational analysis and development of clinical radiolabeled immunoglobulin therapy. Radiother Oncol 41(2):151-61, 11/1996. PMID: 9004359.
84. Quadri SM, Malik AB, Chu HB, Freedman RS, Vriesendorp HM. Intraperitoneal indium-111- and yttrium-90-labeled human IgM (AC6C3-2B12) in nude mice bearing peritoneal carcinomatosis. J Nucl Med 37(9):1545-51, 9/1996. PMID: 8790216.
85. Piamsomboon S, Termrungruanglert W, Kudelka AP, Edwards CL, Freedman RS, Mountain CF, Delclos L, Aapro MS, DeCaro L, Bianca J, Verschraegen CF, Kavanagh JJ. Prolonged stabilization of progressive squamous cell cancer of the cervix with interferon-alpha and 13-cis-retinoic acid: report of two cases and review of the literature. Anticancer Drugs 7(7):800-4, 9/1996. PMID: 8949994.
86. Kudelka AP, Winn R, Edwards CL, Downey G, Greenberg H, Dakhil SR, Freedman RS, Loyer E, Rusinkiewicz J, Gacrama P, Fueger R, Kavanagh JJ. Activity of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Clin Cancer Res 2(8):1285-8, 8/1996. PMID: 9816298.
87. Verschraegen CF, Kudelka AP, Termrungruanglert W, de Leon CG, Edwards CL, Freedman RS, Kavanagh JJ, Vadhan-Raj S. Effects of interleukin-1 alpha on ovarian carcinoma in patients with recurrent disease. Eur J Cancer 32A(9):1609-11, 8/1996. PMID: 8911126.
88. Freedman RS, Platsoucas CD, Deisseroth AB. Use of a retroviral vector to study the trafficking patterns of purified ovarian tumor infiltrating lymphocytes (TIL) used in intraperitoneal adoptive immunotherapy of ovarian cancer patients. A pilot study. Hum Gene Ther 7(11):1351-65, 7/1996. PMID: 8818723.
89. Freedman RS, Tortolero-Luna G, Pandey DK, Malpica A, Baker VV, Whittaker L, Johnson E, Follen Mitchell M. Gestational trophoblastic disease. Obstet Gynecol Clin North Am 23(2):545-71, 6/1996. PMID: 8784889.
90. Fishman A, Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Kaplan AL, Girtanner RE, Kavanagh JJ. Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. J Reprod Med 41(6):393-6, 6/1996. PMID: 8799913.
91. Kudelka AP, Verschraegen CF, Levy T, Edwards CL, Fishman A, Freedman RS, Kaplan A, Kieback DG, Mante R, Ende K, Steger M, Kavanagh JJ. Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs 7(4):398-401, 6/1996. PMID: 8826607.
92. Kavanagh JJ, Kudelka AP, de Leon CG, Tresukosol D, Hord M, Finnegan MB, Kim EE, Varma D, Forman A, Cohen P, Edwards CL, Freedman RS, Verschraegen CF. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 2(5):837-42, 5/1996. PMID: 9816238.
93. Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Levenback C, Chantarawiroj P, Gonzalez de Leon C, Kim EE, Madden T, Wallin B, Hord M, Verschraegen C, Raber M, Kavanagh JJ. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14(5):1552-7, 5/1996. PMID: 8622071.
94. Kudelka AP, Tresukosol D, Gonzalez de Leon C, Termrungruanglert W, Edwards CL, Freedman RS, Tornos C, Kavanagh JJ. Paclitaxel in patients with platinum-resistant ovarian cancer: a selected review of literature and clinical experience. J Med Assoc Thai 79(4):240-5, 4/1996. PMID: 8708510.
95. Lopez A, Tessadrelli A, Kudelka AP, Edwards CL, Freedman RS, Hord M, Kavanagh JJ. Combination therapy with leuprolide acetate and tamoxifen in refractory ovarian cancer. Int J Gynecol Cancer 6:15-19, 1996.
96. Tresukosol D, Kudelka AP, Gonzales de Leon C, Edwards CL, Freedman RS, Mante R, Hord M, Kavanagh JJ. Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer. Eur J Gynaecol Oncol 17(3):188-91, 1996. PMID: 8780916.
97. Lin YC, Kudelka AP, Lawrence D, Verschraegen CF, Kavanagh JJ, Edwards CL, Mante R, Freedman RS. Transcatheter arterial embolization for the control of life-threatening pelvic hemorrhage in a patient with locally advanced cervix carcinoma. Eur J Gynaecol Oncol 17(6):480-3, 1996. PMID: 8971522.
98. Quadri SM, Malik AB, Tang XZ, Patenia R, Freedman RS, Vriesendorp HM. Preclinical analysis of intraperitoneal administration of Indium-111 labeled human tumor reactive monoclonal IgM AC6C3-2B12. Cancer Res 55(23 Suppl):5736s-5742s, 12/1/1995. PMID: 7493338.
99. Nash MA, Platsoucas CD, Wong BY, Wong PM, Cottler-Fox M, Otto E, Freedman RS. Transduction of rIL-2 expanded CD4+ and CD8+ ovarian TIL-derived T cell lines with the G1Na (neor) replication-deficient retroviral vector. Hum Gene Ther 6(11):1379-89, 11/1995. PMID: 8573611.
100. Kavanagh JJ, Tresukosol D, De Leon CG, Edwards CL, Freedman RS, Hord M, Howell E, Lenzi R, Krakoff IH, Kudelka AP. Phase II study of prolonged oral etoposide in refractory ovarian cancer. Int J Gynecol Cancer 5(5):351-354, 9/1995. PMID: 11578503.
101. Kavanagh JJ, Edwards CL, Freedman RS, Finnegan MB, Balat O, Tresukosol D, Burk K, Loechner S, Hord M, Franklin JL. A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer. Gynecol Oncol 58(1):106-9, 7/1995. PMID: 7789874.
102. Kasi LP, Lamki LM, Saranti S, Podoloff DA, Freedman RS. Indium-111 labeled leukocytes in evaluation of active specific immunotherapy responses. Int J Gynecol Cancer 5(3):226-232, 5/1995. PMID: 11578481.
103. Kavanagh J, Tresukosol D, Edwards C, Freedman R, Gonzalez de leon C, Fishman A, Mante R, Hord M, Kudelka A. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. . J Clin Oncol 13:1584-1588, 1995.
104. Soysal O, Balat O, Kudelka AP, Edwards CL, Aladag MA, Colak A, Freedman RS, Kavanagh JJ. Oncogenes and tumor suppressor gene therapy for cancer. (Review). Cancer Molecular Biol 2:591-596, 1995.
105. Freedman RS, Edwards CL, Kavanagh JJ, Kudelka AP, Katz RL, Carrasco CH, Atkinson EN, Scott W, Tomasovic B, Templin S. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. J Immunother Emphasis Tumor Immunol 16(3):198-210, 10/1994. PMID: 7834119.
106. Coleman RL, Keeney ED, Freedman RS, Burke TW, Eifel PJ, Rutledge FN. Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy. Gynecol Oncol 55(1):29-35, 10/1994. PMID: 7959262.
107. Vadhan-Raj S, Kudelka AP, Garrison L, Gano J, Edwards CL, Freedman RS, Kavanagh JJ. Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. J Clin Oncol 12(4):707-14, 4/1994. PMID: 8151314.
108. Freedman RS, Bowen JM, Delcos L, Edwards CL, Wallace S, Atkinson EN, Ioannides CG, Kasi LP, Scott W, Patenia R. Active intralymphatic immunotherapy of uterine cervical carcinoma with viral oncolysate: a pilot study. Int J Gynecol Cancer 4(2):101-110, 3/1994. PMID: 11578392.
109. Freedman RS, Tomasovic B, Templin S, Atkinson EN, Kudelka A, Edwards CL, Platsoucas CD. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. J Immunol Methods 167(1-2):145-60, 1/3/1994. PMID: 8308273.
110. Inskip PD, Eby NL, Cookfair D, Freedman RS, Richardson GS, Wactawski-Wende J, Hoover RN, Boice JD. Serum estrogen and androgen levels following treatment for cervical cancer. Cancer Epidemiol Biomarkers Prev 3(1):37-45, Jan-Feb, 1/1994. PMID: 8118384.
111. Chen PF, Freedman RS, Chernajovsky Y, Platsoucas CD. Amplification of immunoglobulin transcripts by the non-palindromic adaptor polymerase chain reaction (NPA-PCR). Nucleotide sequence analysis of two human monoclonal antibodies recognizing two cell surface antigens expressed in ovarian, cervix, breast, colon and other carcinomas. Hum Antibodies Hybridomas 5(3-4):131-42, 1994. PMID: 7756578.
112. Fisk B, Flytzanes CN, Pollack M, Freedman RS, Wharton JT, Ioannides CG. Characterization of T cell receptor Vb repertoire in ovarian tumor reactive CD3+CD8+CD4-CTL lines. Scan J Immunol 40:591-600, 1994.
113. Kooi S, Freedman RS, Rodriguez-Villanueva J, Platsoucas CD. Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells. Lymphokine Cytokine Res 12(6):429-37, 12/1993. PMID: 8123759.
114. Kudelka AP, Freedman RS, Edwards CL, Lippman SM, Tornos CS, Krakoff IH, Kavanagh JJ. Metastatic adenocarcinoma of the endometrium treated with 13-cis-retinoic acid plus interferon-alpha. Anticancer Drugs 4(3):335-7, 6/1993. PMID: 8358060.
115. Ioannides CG, Fisk B, Pollack MS, Frazier ML, Taylor Wharton J, Freedman RS. Cytotoxic T-cell clones isolated from ovarian tumour infiltrating lymphocytes recognize common determinants on non-ovarian tumour clones. Scand J Immunol 37(4):413-24, 4/1993. PMID: 8469924.
116. Kirk IR, Carrasco CH, Lawrence DD, Chuang VP, Richli WR, Charnsangavej C, Kavanagh JJ, Kudelka AP, Freedman RS, Markowitz AB. Intraperitoneal catheters: percutaneous placement with fluoroscopic guidance. J Vasc Interv Radiol 4(2):299-304, Mar-Apr, 3/1993. PMID: 8481582.
117. Freedman RS, Ioannides CG, Mathioudakis G, Platsoucas CD. Novel immunologic strategies in ovarian carcinoma. Am J Obstet Gynecol 167(5):1470-8, 11/1992. PMID: 1332480.
118. Ioannides CG, Fisk B, Tomasovic B, Pandita R, Aggarwal BB, Freedman RS. Induction of interleukin-2 receptor by tumor necrosis factor alpha on cultured ovarian tumor-associated lymphocytes. Cancer Immunol Immunother 35(2):83-91, 1992. PMID: 1534515.
119. Fromm GL, Freedman RS, Fritsche HA, Atkinson EN, Scott W. Sequentially administered ethinyl estradiol and medroxyprogesterone acetate in the treatment of refractory epithelial ovarian carcinoma in patients with positive estrogen receptors. Cancer 68(9):1885-9, 11/1/1991. PMID: 1833046.
120. Ioannides CG, Freedman RS. Selective usage of TCR V beta in tumor-specific CTL lines isolated from ovarian tumor-associated lymphocytes. Anticancer Res 11(5):1919-25, Sep-Oct, 9/1991. PMID: 1722660.
121. Ioannides CG, Platsoucas CD, Rashed S, Wharton JT, Edwards CL, Freedman RS. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 51(16):4257-65, 8/15/1991. PMID: 1868446.
122. Ioannides CG, Rashed S, Fisk B, Fan D, Itoh K, Freedman RS. Lymphocytes infiltrating ovarian malignant ascites: modulation of IL-2-induced proliferation by IL-4 and of selective increase in CD8+ T cells by TNF-alpha. Lymphokine Cytokine Res 10(4):307-15, 8/1991. PMID: 1932375.
123. Ioannides CG, Freedman RS, Platsoucas CD, Rashed S, Kim YP. Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J Immunol 146(5):1700-7, 3/1/1991. PMID: 1704404.
124. Burke TW, Stringer CA, Morris M, Freedman RS, Gershenson DM, Kavanagh JJ, Edwards CL. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol 40(3):264-7, 3/1991. PMID: 2013451.
125. Freedman RS, Ioannides CG, Tomasovic B, Patenia R, Zhang HZ, Liang JC, Edwards CL. Development of a cell surface reacting human monoclonal antibody recognizing ovarian and certain other malignancies. Hybridoma 10(1):21-33, 2/1991. PMID: 2032733.
126. Ioannides CG, Freedman RS, Patenia R, Bowen JM, Ward NE, O'Brian CA. Immunological effects of tumor vaccines: III. Influenza virus oncolysates inhibit the TPA induced activation of peripheral blood mononuclear cells. In Vivo 5(1):1-6, Jan-Feb, 1/1991. PMID: 1932617.
127. Freedman RS. Biologic response modifiers in gynecologic malignancies. Cancer Bulletin 43:139-145, 1991.
128. Ioannides CG, Freedman RS. T cell responses to ovarian tumor vaccines: identification and significance for future immunotherapy. Int Rev Immunol 7(4):349-64, 1991. PMID: 1685743.
129. Riley LB, Pellis NR, Schantz SP, Freedman RS, Balch CM, Itoh K. Humoral modulation of lymphokine-activated killer (LAK)-cell induction in humans: IgG-related and non-IgG inhibitors in sera from cancer patients. Int J Cancer 46(5):785-91, 11/15/1990. PMID: 2228306.
130. Ioannides CG, Freedman RS, Liskamp RM, Ward NE, O'Brian CA. Inhibition of IL-2 receptor induction and IL-2 production in the human leukemic cell line Jurkat by a novel peptide inhibitor of protein kinase C. Cell Immunol 131(1):242-52, 11/1990. PMID: 2121373.
131. Sandles LG, Freedman RS, Raber MN, Kavanagh J, Edwards CL, Scott WR, Wharton JT. Phase I evaluation of thio-TEPA in combination with cisplatin for advanced gynecologic malignancies. Gynecol Oncol 39(2):139-45, 11/1990. PMID: 2121628.
132. Ioannides CG, Platsoucas CD, Patenia R, Kim YP, Bowen JM, Morris M, Edwards C, Wharton JT, Freedman RS. T-cell functions in ovarian cancer patients treated with viral oncolysates: I. Increased helper activity to immunoglobulins production. Anticancer Res 10(3):645-53, May-Jun, 5/1990. PMID: 2142392.
133. Ioannides CG, Platsoucas CD, Freedman RS. Immunological effects of tumor vaccines: II. T cell responses directed against cellular antigens in the viral oncolysates. In Vivo 4(1):17-24, Jan-Feb, 1/1990. PMID: 2103838.
134. Freedman RS, Ioannides CG. Biological response modifiers in the treatment of gynecologic malignancies. The Cancer Bulletin. 42:98-105, 1990.
135. Lotzová E, Savary CA, Freedman RS, Edwards CL, Morris M. Comparison of recombinant-interleukin-2-activated peripheral blood and tumor-infiltrating lymphocytes of patients with epithelial ovarian carcinoma: cytotoxicity, growth kinetics and phenotype. Cancer Immunol Immunother 31(3):169-75, 1990. PMID: 2337905.
136. Tatman JL, Freedman RS, Scott W, Atkinson EN. Treatment of advanced endometrial adenocarcinoma with cyclic sequential ethinyl estradiol and medroxyprogesterone acetate. Eur J Cancer Clin Oncol 25(11):1619-21, 11/1989. PMID: 2531671.
137. Ioannides CG, Freedman RS, Platsoucas CD. OKT4 monoclonal antibody-induced activation of an autoreactive T-cell clone. Cell Immunol 123(1):244-52, 10/1/1989. PMID: 2570645.
138. O'Keeffe F, Carrasco CH, Charnsangavej C, Richli WR, Wallace S, Freedman RS. Percutaneous drainage and feeding gastrostomies in 100 patients. Radiology 172(2):341-3, 8/1989. PMID: 2501821.
139. Freedman RS, Bowen JM, Atkinson EN, Wallace S, Lotzová E, Silva E, Edwards CL, Delclos L, Scott W, Patenia B. Randomized comparison of viral oncolysate plus radiation and radiation alone in uterine cervix carcinoma. Am J Clin Oncol 12(3):244-50, 6/1989. PMID: 2499178.
140. Ioannides CG, Platsoucas CD, O'Brian CA, Patenia R, Bowen JM, Wharton JT, Freedman RS. Viral oncolysates in cancer treatment: immunological mechanisms of action (review). Anticancer Res 9(3):535-44, May-Jun, 5/1989. PMID: 2669619.
141. Gershenson DM, Wharton JT, Copeland LJ, Stringer CA, Edwards CL, Kavanagh JJ, Freedman RS. Treatment of advanced epithelial ovarian cancer with cisplatin and cyclophosphamide. Gynecol Oncol 32(3):336-41, 3/1989. PMID: 2920954.
142. Ioannides CG, Platsoucas CD, Bowen JM, Wharton JT, Freedman RS. Increased ovarian tumor cell surface reacting antibodies in patients with ovarian adenocarcinoma after viral oncolysate treatment. Anticancer Res 9(1):81-6, Jan-Feb, 1/1989. PMID: 2705759.
143. Furukawa K, Lotzová E, Freedman RS, Bowen JB, Edwards CL, Wharton JT. Effect of virus-modified tumor cell extracts, autologous mononuclear cell infusions and interleukin-2 on oncolytic activity of effector cells of patients with advanced ovarian cancer. Cancer Immunol Immunother 30(2):126-32, 1989. PMID: 2598179.
144. Freedman RS, Kouttab NM, Bowen JM, Edwards CL, Katz RL. Lymphokine activity in malignant effusions after intracavitary viral oncolysate. Lymphokine Res 8(2):115-22, 1989. PMID: 2786595.
145. Freedman RS. Gestational trophoblastic disease. Oncology Overview, 9/1988.
146. Lotzová E, Savary CA, Freedman RS, Edwards CL, Wharton JT. Recombinant IL-2-activated NK cells mediate LAK activity against ovarian cancer. Int J Cancer 42(2):225-31, 8/15/1988. PMID: 3261280.
147. Kong JS, Peters LJ, Wharton JT, Ang KK, Delclos L, Gershenson DM, Copeland LJ, Edwards CL, Freedman RS, Saul PB. Hyperfractionated split-course whole abdominal radiotherapy for ovarian carcinoma: tolerance and toxicity. Int J Radiat Oncol Biol Phys 14(4):737-43, 4/1988. PMID: 3350729.
148. Freedman RS, Edwards CL, Bowen JM, Lotzova E, Katz R, Lewis E, Atkinson N, Carsetti R. Viral oncolysates in patients with advanced ovarian cancer. Gynecol Oncol 29(3):337-47, 3/1988. PMID: 3345954.
149. Metz CA, Freedman RS, Magrina JF. Methylprednisolone in cis-platinum induced nausea and emesis: a placebo-controlled trial. Gynecol Oncol 27(1):84-9, 5/1987. PMID: 3552909.
150. Gershenson DM, Kavanagh JJ, Copeland LJ, Edwards CL, Freedman RS, Wharton JT. High-dose doxorubicin infusion therapy for disseminated mixed mesodermal sarcoma of the uterus. Cancer 59(7):1264-7, 4/1/1987. PMID: 3815302.
151. Larson DM, Copeland LJ, Gallager HS, Gershenson DM, Freedman RS, Wharton JT, Kline RC. Nature of cervical involvement in endometrial carcinoma. Cancer 59(5):959-62, 3/1/1987. PMID: 3815275.
152. Kline RC, Freedman RS, Jones LA, Atkinson EN. Treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with tamoxifen and medroxyprogesterone acetate. Cancer Treat Rep 71(3):327-8, 3/1987. PMID: 2949831.
153. Adelson MD, Johnson TS, Sneige N, Williamson KD, Freedman RS, Peters LJ. Cervical carcinoma DNA content, S-fraction, and malignancy grading. II. Comparison with clinical staging. Gynecol Oncol 26(1):57-70, 1/1987. PMID: 3792936.
154. Ordońez NG, Freedman RS, Herlyn M. Lewis and related tumor-associated determinants on ovarian carcinoma. Gynecol Oncol 26(1):1-10, 1/1987. PMID: 2431961.
155. Roberts DK, Lavia LA, Freedman RS, Horbelt DV, Busby-Walker N. Nuclear and nucleolar areas: a quantitative assessment of endometrial neoplasia. Obstet Gynecol 68(5):705-8, 11/1986. PMID: 3763087.
156. Malone JM, Koonce T, Larson DM, Freedman RS, Carrasco CH, Saul PB. Palliation of small bowel obstruction by percutaneous gastrostomy in patients with progressive ovarian carcinoma. Obstet Gynecol 68(3):431-3, 9/1986. PMID: 2426641.
157. Hancock KC, Freedman RS, Edwards CL, Rutledge FN. Use of cisplatin, doxorubicin, and cyclophosphamide to treat advanced and recurrent adenocarcinoma of the endometrium. Cancer Treat Rep 70(6):789-91, 6/1986. PMID: 3731140.
158. Savage HE, Rossen RD, Hersh EM, Freedman RS, Bowen JM, Plager C. Antibody development to viral and allogeneic tumor cell-associated antigens in patients with malignant melanoma and ovarian carcinoma treated with lysates of virus-infected tumor cells. Cancer Res 46(4 Pt 2):2127-33, 4/1986. PMID: 3948184.
159. Freedman RS, Saul PB, Edwards CL, Jolles CJ, Gershenson DM, Jones LA, Atkinson EN, Dana WJ. Ethinyl estradiol and medroxyprogesterone acetate in patients with epithelial ovarian carcinoma: a phase II study. Cancer Treat Rep 70(3):369-73, 3/1986. PMID: 2937533.
160. Jolles CJ, Freedman RS, Hamberger AD, Horbelt DV. Complications of extended-field therapy for cervical carcinoma without prior surgery. Int J Radiat Oncol Biol Phys 12(2):179-83, 2/1986. PMID: 3949567.
161. Cox CJ, Freedman RS, Fritsche HA. Lacto-N-Fucopentaose III activity in the serum of patients with ovarian carcinoma. Gynecol Obstet Invest 21:164-168, 1986.
162. Lotzová E, Savary CA, Freedman RS, Bowen JM. Natural immunity against ovarian tumors. Comparative Immunology, Microbiology, and Infectious Diseases 9:269-275, 1986.
163. Gershenson DM, Copeland LJ, Kavanagh JJ, Cangir A, Del Junco G, Saul PB, Stringer CA, Freedman RS, Edwards CL, Wharton JT. Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vincristine, dactinomycin, and cyclophosphamide. Cancer 56(12):2756-61, 12/15/1985. PMID: 2996746.
164. Freedman RS. Recent immunologic advances affecting the management of ovarian cancer. Clin Obstet Gynecol 28(4):853-71, 12/1985. PMID: 4075635.
165. Shirey DR, Kavanagh JJ, Gershenson DM, Freedman RS, Copeland LJ, Jones LA. Tamoxifen therapy of epithelial ovarian cancer. Obstet Gynecol 66(4):575-8, 10/1985. PMID: 4047546.
166. Keeney ED, Freedman RS, Drewinko B, Rutledge FN, Atkinson EN. Clinical evaluation of high-dose cytarabine and cisplatin in recurrent cervical carcinoma. Cancer Treat Rep 69(9):1023-5, 9/1985. PMID: 4040808.
167. Horbelt DV, Freedman RS, Roberts DK, Walker NJ, Edwards CL, Jones LA. An ultrastructural comparison of grade I and II endometrial adenocarcinoma considering estrogen and progesterone receptor status. Gynecol Oncol 18(2):150-6, 6/1984. PMID: 6735260.
168. Lotzová E, Savary CA, Freedman RS, Bowen JM. Natural killer cell cytotoxic potential of patients with ovarian carcinoma and its modulation with virus-modified tumor cell extract. Cancer Immunol Immunother 17(2):124-9, 1984. PMID: 6205745.
169. Freedman RS, Bowen JM, Atkinson EN, Scott W, Wagner S. Virus-augmented delayed hypersensitivity skin tests in gynecological malignancies. Cancer Immunol Immunother 17(2):142-6, 1984. PMID: 6088033.
170. Jolles CJ, Freedman RS, Jones LA. Estrogen and progestogen therapy in advanced ovarian cancer: preliminary report. Gynecol Oncol 16(3):352-9, 12/1983. PMID: 6654179.
171. Freedman RS, Bowen JM, Herson JH, Wharton JT, Edwards CL, Rutledge FN. Immunotherapy for vulvar carcinoma with virus-modified homologous extracts. Obstet Gynecol 62(6):707-14, 12/1983. PMID: 6633995.
172. Jones LA, Edwards CL, Freedman RS, Tan MT, Gallager HS. Estrogen and progesterone receptor titers in primary epithelial ovarian carcinomas. Int J Cancer 32(5):567-71, 11/15/1983. PMID: 6315602.
173. Hannigan EV, Freedman RS, Elder KS, Rutledge FN. Reexploration after treatment for uterine sarcoma. Gynecol Oncol 16(1):1-5, 8/1983. PMID: 6884821.
174. Hannigan EV, Freedman RS, Elder KW, Rutledge FN. Treatment of advanced uterine sarcoma with adriamycin. Gynecol Oncol 16(1):101-4, 8/1983. PMID: 6884822.
175. Hannigan EV, Freedman RS, Elder KW, Rutledge FN. Treatment of advanced uterine sarcoma with vincristine, actinomycin D, and cyclophosphamide. Gynecol Oncol 15(2):224-9, 4/1983. PMID: 6687580.
176. Hannigan EV, Freedman RS, Rutledge FN. Adjuvant chemotherapy in early uterine sarcoma. Gynecol Oncol 15(1):56-64, 2/1983. PMID: 6401640.
177. Davis JW, Freedman RS, Atkinson N, Bowen JM. Augmentation of in vitro lymphocyte blastogenesis and cytotoxicity responses by tumor cells modified with dodecanoyl cytochrome C. Nat Immun Cell Growth Regul 3(4):203-9, 1983. PMID: 6098830.
178. Freedman RS, Gutterman JU, Wharton JT, Rutledge FN. Leukocyte interferon (IFN alpha) in patients with epithelial ovarian carcinoma. J Biol Response Mod 2(2):133-8, 1983. PMID: 6644331.
179. Fritsche HA, Freedman RS, Liu F, Acomb LD, Collinsworth WL. A survey of tumor markers in patients with squamous cell carcinoma of the uterine cervix. Gynecol Oncol 14(2):230-5, 10/1982. PMID: 6182055.
180. Freedman RS, Bowen JM, Leibovitz A, Pathak S, Siciliano MJ, Gallager HS, Giovanella BC. Characterization of a cell line (SW756) derived from a human squamous carcinoma of the uterine cervix. In Vitro 18(8):719-26, 8/1982. PMID: 7129487.
181. Boice CR, Freedman RS, Herson J, Wharton JT, Rutledge FN. Bleomycin and mitomycin-C (BLM-M) in recurrent squamous uterine cervical carcinoma. Cancer 49(11):2242-5, 6/1/1982. PMID: 6176311.
182. Hammond JA, Herson J, Freedman RS, Hamberger AD, Wharton JT, Wallace S, Rutledge FN. The impact of lymph node status on survival in cervical carcinoma. Int J Radiat Oncol Biol Phys 7(12):1713-8, 12/1981. PMID: 7199519.
183. Carlson JA, Freedman RS, Wallace S, Chuang VP, Wharton JT, Rutledge FN. Intraarterial cis-platinum in the management of squamous cell carcinoma of the uterine cervix. Gynecol Oncol 12(1):92-8, 8/1981. PMID: 6168518.
184. Freedman RS. Methotrexate in gestational trophoblastic disease. The Cancer Bulletin 33:63-66, 1981.
185. Siciliano MJ, Bordelon-Riser ME, Freedman RS, Kohler PO. A human trophoblastic isozyme (lactate dehydrogenase-Z) associated with choriocarcinoma. Cancer Res 40(2):283-7, 2/1980. PMID: 7356510.
186. Freedman RS, Bowen J, Herson J, Wharton JT, Rutledge FN. Tumor antigenicity and the immune system in gynecological cancer: a review. Gynecol Oncol 9(1):43-62, 2/1980. PMID: 6243598.
187. Freedman RS, Herson J, Wharton JT, Rutledge FN. Single-agent chemotherapy for recurrent carcinoma of the cervix. Cancer Clin Trials 3(4):345-50, 1980. PMID: 6775827.
188. Freedman RS, Herson J, Bowen JM, Wharton JM, Rutledge FN, Hamberger AD. Virus modified homologous tumor cell extract in the treatment of vulvar carcinoma. Cancer Immunol Immunother 8:33-38, 1980.
189. Wallace S, Jing BS, Zornoza J, Hammond JA, Hamberger A, Herson J, Freedman RS, Wharton JT. Current concepts in cancer: Updated cervix cancer II. Stages IB and II. Is lymphangiography worthwhile? Int J Radiat Oncol Biol Phys 5:1863-1876, 1979.
190. Freedman RS, Pihl E, Kusyk C, Gallager HS, Rutledge F. Characterization of an ovarian carcinoma cell line. Cancer 42(5):2352-9, 11/1978. PMID: 719612.
191. Freedman RS, Wharton JT, Rutledge F, Sinkovics JG. Transfer factor and possible applications in gynecology. Am J Obstet Gynecol 130(5):572-84, 3/1/1978. PMID: 343596.
192. Van der Walt LA, Freedman RS. The significance of serum oestradiol and progesterone levels in evaluating the response to clomiphene citrate. S Afr Med J 50(30):1171-2, 7/14/1976. PMID: 968662.
193. Foden AP, Freedman RS, Abrahams C. Scanning electron microscopy of normal uterine cervix, carcinoma in situ and squamous cell carcinoma. Preliminary findings. S Afr Med J 50(15):571-3, 4/3/1976. PMID: 1265553.
194. Freedman RS, van der Walt LA. Treatment of anovulation with human menopausal gonadotrophin. S Afr Med J 50(13):519-22, 3/24/1976. PMID: 1265551.
195. Freedman RS, Shippel S, Hawkins DM. Effects of breast-feeding practice on the post-partum endometrium. S Afr J Med Sci 41(2):99-108, 1976. PMID: 968653.
196. Freedman RS. Pathophysiology of anovulation. The Leech. Witwatersrand University Press, 1976.
197. Tyson JE, Freedman RS, Perez A, Zacur HA, Zanartu J. Significance of the secretion of human prolactin and gonadotropin for puerperal lactational infertility. Ciba Found Symp(45):49-71, 1976. PMID: 801807.
198. Schoub BD, Jacobs UR, Hyten E, Freedman RS. The role of mycoplasma in human infertility. S.A. Med J 50:571, 1976.
199. Freedman RS, Van der Walt LA. Human placental lactogen and plasma total oestriol values in the third trimester of pregnancy. S Afr Med J 49(43):1777-80, 10/11/1975. PMID: 1242544.
200. Freedman RS. Histology and histochemistry of the ovary during pregnancy and in the postpartum period. S Afr Med J 49(30):1226-7, 7/16/1975. PMID: 1154181.
201. Freedman RS, Joosting AC, Ryan JT, Nkoni S. A study of associated factors, including genital herpes, in Black women with cervical carcinoma in Johannesburg. S Afr Med J 48(41):1747-52, 8/24/1974. PMID: 4369733.
202. Freedman RS. Aspects of Bantu domestic life in relation to some gynaecological conditions. S Afr Med J 46(38):1383-6, 9/23/1972. PMID: 4565004.
203. Freedman RS. Gynaecology in Southern Africa. Charleswood, G.P., Witwatersrand University 43:344-364, 1972.
204. Gordon Y, Freedman RS. Premature rupture of membranes. S Afr J Obstet Gynaec, 1971.
205. Freedman RS, Berry A. Progesterone deficiency in pregnancy. S Afr J Obstet Gynaec 8:72-76, 1970.

Invited Articles

1. Freedman RS. Editorial Comment: Staging early ovarian cancer: Impact on treatment decisions. European J Cancer 46:856-8, 2010.
2. Telesca D, Mueller P, Parmigiani G, Freedman R. Modeling Dependent Gene Expression. Working Paper. Harvard University Working Paper Series 114, 2010.
3. Dixon DO, Freedman RS, Herson J, Hughes M, Kim K, Silverman MH, Tangen CM. Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees. Clin Trials 3:314-9, 2006. PMID: 16895048.
4. Freedman RS, Deavers M, Liu J, Wang E. Peritoneal inflammation - A microenvironment for Epithelial Ovarian Cancer (EOC). J Transl Med 2:23, 6/2004. PMID: 15219235.
5. Hwu P, Freedman RS. The immunotherapy of patients with ovarian cancer. J Immunother 25(3):189-201, 5/2002. PMID: 12000860.
6. Melichar B, Freedman RS. Immunology of the peritoneal cavity: relevance for host-tumor relation. Int J Gynecol Cancer 12(1):3-17, 2002. PMID: 11860531.
7. Nash M, Ferrandina G, Gordinier M, Loercher A, Freedman RS. The role of cytokines in both the normal and malignant ovary. Endocrine-Related Cancer (review article) 6:93-107, 1999.
8. Butts C Freedman RS. Vaccines for ovarian carcinoma. . Cancer Control 6:335-342, 1999.
9. Freedman RS, Lenzi R, Kudelka AP, Lawrence DD, Rosenblum M, Platsoucas CD. Intraperitoneal immunotherapy of peritoneal carcinomatosis. Cytokines Cell Mol Ther 4(2):121-40, 6/1998. PMID: 9681251.
10. Freedman RS, Brown B. Adjuvant Therapy. S. Eva Singletary (ed) . Breast Diseases: A Year Book Quarterly 8:373-374, 1998.
11. Gordinier ME Freedman RS. Conservative management of endometrial cancer in the premenopausal woman. M.D. Anderson Oncology (Case Reports & Review), 1998.
12. Platsoucas CD, Freedman RS. Tumor infiltrating lymphocytes (TIL) in gene therapy. Cancer Bulletin 45:118-124, 1993.
13. Freedman RS. Biologic response modifiers in gynecologic malignancies. Cancer Bulletin 43:139-145, 1991.
14. Freedman RS, Ioannides CG. Biological response modifiers in the treatment of gynecologic malignancies. Cancer Bulletin 42:98-105, 1990.
15. Freedman RS. Oncology overview on gestational trophoblastic disease. Oncology Overview, International Cancer Research Data Bank Program, National Cancer Institute, 9/1988.
16. Freedman RS. Epithelial ovarian cancer. Oncology Update 5:1-13, 1988.
17. Freedman RS. Gestational trophoblastic disease. Cancer Bulletin 38(6):290-293, 1986.
18. Freedman RS. Editorial Commentary: Diagnosis and treatment of ovarian cancer. Oncology Overview, International Cancer Research Data Bank Program, National Cancer Institute, 11/1984.
19. Freedman RS. Intraperitoneal immunotherapy in a patient with ovarian carcinoma. Cancer Bulletin 36(5):250-251, 1984.
20. Freedman RS. Methotrexate in gestational trophoblastic disease. Cancer Bulletin 33:63-66, 1981.

Editorials

1. Freedman R. Viewpoints: Could a clinical trial be the right move for you? Houston Chronicle, 09/18/2010, 9/2010.
2. Freedman RS. Female Genital Tract. 1988 Year Book of Cancer:174; 175; 176; 178; 179; 180; 182; 184; 187, 1988.
3. Freedman RS. Female Genital Tract. 1987 Year Book of Cancer:275; 177; 178; 183; 184; 185, 1987.
4. Freedman RS. Editorial - The importance of breast feeding. S.A. J Obstet Gynaec, 3/1975.
Other Articles
1. Bitran JD, Freedman RS, O'Dwyer PJ, Zincke H. Expanding clinical applications of thiotepa. Cancer Chemotherapy Monographs, 1989.
2. Freedman RS. The control of chemotherapy-induced nausea and emesis. Current Hospital Topics, Upjohn, 1986.

Abstracts

1. Escalante CP, Oh JH, Baum DD, Mante M, Zalpour A, Spivey S, Stewart C, Ensor J, Grover T, Freedman RS. Immediate adverse reactions to chemotherapy: experience of a large ambulatory treatment center. Proc of ASCO 24:8558a, 2006.
2. Escalante CP, Oh JH, Baum DD, Mante M, Zalpour A, Spivey S, Stewart C, Ensor J, Grover T, Freedman RS. Immediate adverse reactions to chemotherapy: experience of a large ambulatory treatment center. Proc of ASCO 24:8558a, 2006.
3. Hu W, Kavanagh JJ, Deavers M, Fu S, Johnson D, Freedman RS, Verschraegen C, Sen S. Frequent over-expression of STK15/AURORA-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. Proc of AACR 46:5742a, 2005.
4. Apte S, Vadhan-Raj S, Cohen L, Yang Y, Levenback C, Ramirez PT, Iyer R, Gallardo S, Garcia M, Freedman RS. Hemapoietic, immunomodulatory, antitumor, and toxicity profiles of sequential GM-CSF and IFN-gamma 1b biotherapy and carboplatin in recurrent ovarian carcinoma. Proc of ASCO 23:5053a, 2005.
5. Gordon IO Freedman RS. Monocytes and macrophages in epithelial ovarian cancer are deficient Fc?R mediated functions. Proc of AACR 46:2440a, 2005.
6. Hu W, Chen L, Wu W, Bolanos-Clark M, Verschraegen C, Yeung S-C, Kudelka A, Freedman RS, Kavanagh JJ. Enhancing tumor killing with the combined treatment of Manumycin and Paclitaxel-resistant ovarian cancer cells. Proc of AACR, 2004.
7. Okrent IA Freedman RS. Monocyte and Macrophage (MO/MA) Subpopulations in Epithelial Ovarian Cancer (EOC). Proc of AACR 45:1259a, 2004.
8. Wang E, Ngalame Y, Panelli MC, Nguyen-Jackson H, Deavers M, Mueller P, Hu W, Savary C, Freedman RS, Marincola FM. Peritoneal and sub-peritoneal stroma may facilitate regional spread of ovarian cancer. Proc of AAC 45:1778a, 2004.
9. Hu W, Verschraegen CF, Wu W, Lu K, Liu J, Yung MS, Kudelka AP, Freedman R, Kavanagh JJ. Differential protein profile analysis of sera from normal donors and ovarian cancer patients. Proc of AACR 43:37, 2002.
10. Melichar B, Patenia R, Templin S, Melicharová K, Freedman R. Effects on epithelial ovarian carcinoma cells and monocyte cytotoxicity induced by recombinant human soluble CD40L ligand trimer (rhuCD40L) + recombinant interferon gamma (rIFN-g). Proc of AACR 43:442, 2002.
11. Hu W, Verschraegen CF, Wu W, Freedman R, Kudelka AP, Kavanagh JJ, Yeung, J. Enhanced apoptotic effect of heat shock protein inhibitor in combination with farnesyl transferase inhibitors (FTI) on ovarian and mesothelioma cancer cells. Proc of AACR 43:600, 2002.
12. Butts CL, Savary CA, Vadhan-Raj, S, Freedman RS. IL-12 and IL-10 production in dendritic cell cultures from peritoneal exudate cells (PEC) and peripheral blood mononuclear cells (PBMCs) of patients with epithelial ovarian cancer following treatment in vitro with soluble CD40 ligand (CD40L). Proc of AACR 43:973, 2002.
13. Melichar B, Lenzi R, Rosenblum M, Verschraegen C, Kudelka A, Kavanagh J, Melicharova K, Templin S, Garcia M, Abbruzzese J, Freedman R. Peritoneal fluid (PF) neopterin, nitrate and tryptophan after intraperitoneal (IP) administration of interleukin-12 (IL-12). Proc of ASCO 21:17a, 2002.
14. Freedman RS, Vadhan-Raj S, Verschraegen C, Kavanagh J, Levy L, Atkinson EN, Kudelka AP, Butts C, Folloder J, Garcia M, Caron D. Pilot study of Flt3 ligand in patients with peritoneal carcinomatosis. Proceedings of ASCO 21:20a, 2002.
15. Verschraegen C, Hu W, Freedman RS, Kudelka AP, Kavanagh JJ, Yeung SJ. Growth inhibitory effect on FTI alone and in combination with Quercetin on ovarian cancer cell lines. Proc of AACR 42 (#2623), 2001.
16. Hu W, Wu W, Yeung SJ, Kavanagh JJ, Freedman RS, Mao L, Verschraegen C. Increased expression of HSP 70 in ovarian cancer cell line following treatment with FTI. Proc of AACR 42 (#2627), 2001.
17. Donato ML, Aleman AS, Gershenson DM, Wharton JT, Bast RC Jr, Burke TW, Bodurka-Bevers D, Bevers MW, Levenback CF, Wolf JK, Freedman RS, Cooke S, Ippoliti C, Brewer M, Gajewski JL, Champlin RE. Long-term results of 102 patients with advanced ovarian cancer treated with high-dose chemotherapy. Proc of ASCO 20:204a, 2001.
18. Vadhan-Raj S, Kavanagh JJ, Freedman RS, Folloder J, Currie LM, Bueso-Ramos CE, Hoots WK, Connor J, Verschraegen C, Wolf JK, Wharton J, Lichtiger B. Successful transfusions of recombinant human Thrombopoietin (rhTPO)-derived autologous platelets cryopreserved with tromobosol and 2% DMSO to support carboplatin-associated severe thrombocytopenia. Proc of ASCO 20:8a, 2001.
19. Zhang W, Lenzi R, Platsoucas CD, Freedman RS, Abbruzzese JL, Rosenblum M. Clinical pharmacology studies of rhIL-12 administered by the IP route. . Proceed of AACR 41:194 (#1238), 2000.
20. Butts C, Templin S, Peng C, Freedman RS. IL-12 production by dendritic cells in the peritoneal cavity of patients with epithelial ovarian cancer following in vitro treatment with GM-CSF and IL-4. Proceed of AACR 41:621 (#3946), 2000.
21. Loercher AE, Kavanagh JJ, Kudelka A, Verschraegen C, Freedman RS. In vitro differentiation of suppressor monocytes to immunostimulatory cells by the addition of TNF-a and IFN-g. Proceed of AACR 41:193 (#1233), 2000.
22. Lee, LYL, Loercher AE, Lenzi R, Kudelka A, Platsoucas CD, Freedman RS. In vitro effects of rhIL-12 on cytokine production by peripheral blood mononuclear cells and purified T cells from normal subjects and patients with epithelial ovarian cancer. Proceed of AACR 41:193 (#1234), 2000.
23. Ferrandina GM, Raspaglio G, Ranelletti FO, Morizio V, Ferlini C, Filippini F, D'Inglullo S, Mancuso S, Freedman RS, Scambia G. Role of mitogen-activated kinases (MAPK) and effects of specific MAPK-inhibitors on the EGF-promoted biological activities in HEP2 human laryngeal cancer cells. Proceed of AACR 41:403 (#2563), 2000.
24. Nash MA, Bhala R, Freedman RS. Studies on the effect of decorin on the growth of ovarian cancer cells. Proceed of AACR 41:861 (#5467), 2000.
25. Verschraegen CF, Hu W, Wu W, Mendoza J, Freedman RS. The effect of growth inhibition by ALRT 1550 alone and in combination with interferon-g. Proceed of AACR:274 (#1746), 2000.
26. Donato ML, Gershenson DM, Ippoliti C, Wharton JT, Bevers MW, Bodurka-Bevers DC, Levenback CF, Wolf JK, Freedman RS, Bast RC, Burke TW, Champlin RE. Topotecan in combination with cyclophosphamide and melphalan for stem cell transplantation: Results of a large phase I trial in advanced ovarian cancer. Proceed of AACR 41:50 (#192), 2000.
27. Lenzi R, Kudelka A, Verschraegen C, Nash M, Loercher A, Zhang HZ, Katz RL, Abbruzzese JL, Kavanagh JJ, Platsoucas CD, Rosenblum M, Freedman RS. Intraperitoneal administration of human recombinant interleukin-12 (rhIL-12) for the treatment of ovarian and GI cancer patients with progressive disease after standard chemotherapy (T97-0034). Molecular Targets and Cancer Therapeutics, sponsored by AACR-NCI-EORTC, Washington, D.C. 11/1999.
28. Kudelka AP, Verschraegen C, Edwards CL, Freedman RS, Plunkett WK, Nicol S, Kavanagh JJ. A preliminary report of a phase II study of gemcitabine in women with platinum refractory Müllerian (ovarian, fallopian tube and primary peritoneal) carcinomas. Proceed of ASCO 18:377 (#1457), 1999.
29. Verschraegen C, Hu W, Mendoza J, Du Y, Kudelka AP, Freedman RS, Kavanagh JJ, Giovanella B. Characterization of twenty-three Müllerian cell lines derived from primary ovarian cancers. Proceed of AACR 40:491 (#3291), 1999.
30. Kudelka AP, Freedman RS, Kavanagh JJ, Verschraegen C, Scott W, Edwards CL, Nash M, Levy L, Atkinson EN, Platsoucas CD. Clinical and biologic effects of intraperitoneal (IP) injections of recombinant interferon-gamma and recombinant interleukin-2 (rpatients with ovarian or peritoneal carcinoma. Proceed of AACR 40:572 (#3774), 1999.
31. Melichar B, Nash M, Lenzi R, Platsoucas CD, Freedman RS. Coexpression of B7 costimulatory molecules and CD28 and CTLA-4 on tumor infiltrating lymphocytes (TIL) from patients with peritoneal carcinomatosis. Proceed of AACR 40:574 (#3775), 1999.
32. Kim YM, Zavadova E, Loercher A, Freedman RS. Comparison of media conditions to expand TIL-derived T-cell lines from patients with peritoneal carcinomatosis including serum free, rIFN-g and polyenzyme preparation. Proceed of AACR 40:183 (#1220), 1999.
33. Pappas J, Reveille JD, Gaughan J, Sakkas LI, Freedman RS, Platsoucas CD. HLA-DRB1, -DQA1 and -DQB1 alleles in ovarian carcinoma. Proceed of AACR 40:497 (#3283), 1999.
34. Loercher A, Kavanagh JJ, Verschraegen C, Platsoucas CD, Freedman RS. Induction of IL10 secreting monocytes using peripheral blood mononuclear leukocytes of patients with epithelial ovarian cancer (EOC) cultured in the presence of rGM-CSF and rIL-2. Proceed of AACR 40:573 (#3776), 1999.
35. Freedman RS, Platsoucas CD, Schlom J, Salazar E, Melichar B, Nash M, Kudelka AP, Verschraegen C, Kavanagh J, Abbruzzese JL. Infection of fresh epithelial ovarian carcinoma (EOC) cells with a canary pox construct ALVAC-hB7.1 after in vitro treatment with rIFN-g and early clinical results. Proceed of AACR 40:575 (#3792), 1999.
36. Lenzi R, Kudelka AP, Verschraegen C, Nash M, Loercher A, Zhang H-Z, Katz RL, Abbruzzese JL, Kavanagh JJ, Platsoucas CD, Freedman RS. Intraperitoneal (IP) bioimmunologic responses in patients with ovarian and gastrointestinal cancers at a low toxicity dosing schedule of IP recombinant interleukin-12 (rhIL-12). Proceed of AACR 40:573 (#3778), 1999.
37. Zavadova E, Savary C, Freedman RS. Maturation of dendritic cells (DC) from ovarian cancer patients. . AACR-NCI-EORTC Internat. Conf. Wash, D.C., Nov 16-19, 1999 5(Suppl) (#152), 1999.
38. Hu W, Wu W, Kuang J, Mendoza J, Kudelka AP, Freedman RS, Kavanagh JJ, Sen S, Zhou HY, Verschraegen C. Overexpression of STK15/BTAK correlates with increased malignancy of ovarian cancer cell lines. Proceed of AACR 40:371 (#2458), 1999.
39. Donato M, Gershenson D, Wharton JT, Aleman A, Ippoliti C, Bodurka D, Levenback C, Bevers M, Wolf J, Freedman R, Gajweski J, Bast R, Champlin RE. Phase I study of high-dose topotecan and alkylating agents for advanced ovarian cancer. Proceed of ASCO 18:44 (#164), 1999.
40. Steger M, Kudelka AP, Freedman RS, Verschraegen C, Hu, W, Du Y, Kavanagh JJ. Phase II study of SB-75 a LHRH antagonist in patients with ovarian cancer. Proceed of ASCO 18:362 (#1398), 1999.
41. Lenzi R, Kudelka AP, Verschraegen C, Nash M, Loercher A, Zhang HZ, Katz RL, Abbruzzese JL, Kavanagh JJ, Platsoucas CD, Freedman RS. Recombinant human interleukin-12 (rhIL-12) in patients with ovarian and gastrointestinal cancers. Evidence of biological activity and lack of significant toxicity with low-dose intraperitoneal (IP) administration. Proceed of ASCO 18:446 (#1721), 1999.
42. Hu W, Verschraegen C, Wu WG, Mendoza J, Freedman RS, Kavanagh JJ, Nash MA. Resistance to TGF-b in cell lines derived from ovarian cancers is related to low expression of DPC-4. Proceed of AACR 40:562 (#3707), 1999.
43. Nash M, Lenzi R, Platsoucas CD, Freedman RS. RT-PCR quantitation of cytokine responses in vivo from specimens containing small numbers of cells during bioimmunotherapy. Proceed of AACR 40:80 (#536), 1999.
44. Pappas J, Lin WL, Helm CW, B, Freedman RS, Platsoucas CD. Substantial proportions of identical T cell receptor transcripts in ovarian tumor infiltrating lymphocytes. Proceed of AACR 40:499 (#3294), 1999.

Book Chapters

1. Zand B, Freedman RS. Early-Stage Ovarian Cancer. In: Encyclopedia of Cancer. Part 5, 1196-1200, 2012.
2. Freedman RS. Intraperitoneal therapy in ovarian cancer: immunotherapy. In: Intraperitoneal Cancer Therapy. Humana Press, Inc. Totowa, NJ, 2007.
3. Kudelka AP, Freedman, RS, Kavanagh JJ. Gestational trophoblastic tumors. Chapter 24. In: Cancer Management: a multidisciplinary approach, 2004.
4. Ramirez P, Freedman RS. Gynecologic problems in patients with breast cancer. Chapter 14. In: MD Anderson Cancer Care Series, Breast Cancer. Springer-Verlag: New York, 382-405, 2001.
5. Freedman RS, Kudelka AP, Verschraegen CF, Platsoucas, CD. Progress Toward Tumor Specific Immunity in Carcinomas of the Ovary and Breast. In: Cancer in Women. Blackwell Science, Inc., 30-53, 1998.
6. Page RD, Kavanagh JJ, Edwards CL, Kudelka AP, Freedman RS, Kavanagh JJ. Gestational Trophoblastic Tumors. In: Medical Oncology: A Comprehensive Review. PRR, 377-391, 1996.
7. Kudelka AP, Page, RD Freedman RS, Kavanagh JJ. Gestational trophoblastic tumors. Chapter 23. In: Cancer Management: A multidisciplinary approach. 1996.
8. Freedman RS, Platsoucas CD. Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes. In: Cancer Treat Res. 82, 115-46, 1996. ISBN: 8849947.
9. Freedman RS, Edwards CL, Bowen JM, Tomasovic B, Patenia R, Scott W. Regional clinical responses following intraperitoneal injection of allogeneic viral oncolysate in patients with epithelial ovarian carcinoma (Heidelberg, Germany). In: 2nd European Congress in Gynaecological Endoscopy and New Surgical Techniques. Monduzzi Editore, 35-42, 1994.
10. Freedman RS. Conventional treatment results in epithelial ovarian cancer. In: Autologous Bone Marrow Transplantation. Cancer Treatment Research Education Fund, 183-191, 1993.
11. Jones LA, Press MF, Holt JA, Gallager HS, Freedman RS, Edwards CL. Comparison of immunologic and steroid-binding assays for estrogen receptors in human ovarian carcinomas. In: Gynecologic Cancer: Diagnosis and Treatment Strategies. University of Texas Press, 111-121, 1987.
12. Lotzová E, Savary CA, Freedman RS, Bowen JM. Natural killer cell antitumor activity in patients with ovarian carcinoma: Induction of cytotoxicity by viral oncolysates and interleukin-2. In: Gynecology Cancer: Diagnosis and treatment Strategies. University of Texas Press, 123-126, 1987.
13. Lotzová E, Savary CA, Freedman RS, Bowen JM. NK cell antitumor activity of patients with ovarian carcinoma. Induction of cytotoxicity by viral oncolysates and interleukin-2. In: Gynecologic Cancer: Diagnosis and Treatment Strategies. University of Texas Press, 1987.
14. Fritsche HA, Freedman RS, Liu FJ, Cox CJ. Tumor markers for gynecologic cancers. In: Gynecologic Cancer: Diagnosis and Treatment Strategies. University of Texas Press, 385-396, 1987.
15. Freedman RS, Bowen JM, Lotzová E, Edwards CL, Lewis E, Katz RL. Virus augmentation as a biologic-modifier approach: Experience with intracavitary virus-augmentation therapy. In: Gynecologic Cancer: Diagnosis and Treatment Strategies. University of Texas Press, 137-157, 1987.
16. Freedman RS. The control of chemotherapy-induced nausea and emesis. In: Monograph. The Upjohn Company, 1986.
17. Freedman RS. Recent immunological advances affecting the management of ovarian cancer. In: Clinical Obstetrics and Gynecology. 28, No. 4. J.B. Lippincott Company, Publishers, 849-867, 1985.
18. Freedman RS, Bowen JM, Herson J, Wharton JT, Rutledge FN. Experience in TFd in advanced gynecological cancer and two nongynecological sarcomas. In: Immune Regulators in Transfer Factor. Academic Press, Inc., 597-604, 1979.

Books (edited and written)

1. Hunt KK, Robb GL, Strom EA, Ueno NT. Breast Cancer, 2nd Ed. In: MD Anderson Cancer Care Series 7. Series Ed(s) Buzdar AU, Freedman RS (Series Editors). 7, 2008.
2. DeMonte F, Gilbert MR, Mahajan A, McCutcheon IE. Tumors of the Brain and Spine. In: MD Anderson Cancer Care Series. Series Ed(s) Buzdar AU, Freedman RS (Series Editors). 6, 2007.
3. Eifel PJ, Gershenson DM, Kavanagh JJ, Silva EG. Gynecologic Cancer. In: MD Anderson Cancer Care Series. Series Ed(s) Buzdar AU, Freedman RS (Series Editors), 2006.
4. Ajani JA, Curley SA, Janjan NA, Lynch PM. Ed(s) Buzdar AU, Freedman RS. Gastrointestinal Cancer. In: The M.D. Anderson Cancer Care Series. Series Ed(s) Buzdar AU, Freedman RS. 3. Springer Science+Business Media, Inc: New York, NY, 2005.
5. Chan KW, Raney RB Jr. Ed(s) Buzdar AU, Freedman RS (Series Editors). Pediatric Oncology. In: The M.D. Anderson Cancer Care Series. Series Ed(s) Buzdar AU, Freedman RS. 4. Springer Science + Business Media, Inc. New York, 2005.
6. Fossella FV, Komaki R, Putnam JB Jr. Ed(s) Buzdar AU, Freednan RS (Series Editors). Lung Cancer. In: The MD Anderson Cancer Care - Series 2. Series Ed(s) Buzdar AU, Freednab RS (Series Editors), 2003.

Letters to the Editor

1. Kudelka AP, Lenzi R, Atkinson EN, Levy LB, Freedman RS. Is ascitic fluid interleukin-12 an independent prognostic factor in ovarian cancer? The necessity of correction milligram P values for multiple comparisons. J Clin Oncol 16(9):3208-9, 9/1998. PMID: 9738599.

Manuals, Teaching Aids, Other Teaching Publications

1. Journey to Health: Mind-Body-Spirit. Produced by Public Education Office (MDACC) and Dallas County Community College District, 9/2003.
2. Gynecology Manual (contribution), 2000.
3. Lecture Series on Immunology (given annually to Fellows, Residents). 2000.
4. Freedman RS, Edwards CL, Bowen JM, Tomasovic B, Patenia, Scott W. Regional clinical responses following intraperitioneal injection of allogeneic viral oncolysante in patients with epithelial ovarian carcinoma. Ed(s) Bastert G, Wallwiener D, Keckstein J. Monduzzi Editore - International Proceedings Division: Bologna, Italy, 1993.
5. Video Tape: "Current Trends in Anti-emetic Therapy". Produced by the Upjohn International Inc., Kalamazoo MI. Filmed by M.D. Anderson Biomedical Communications Department, 5/1986.

Last updated: 6/13/2016